Zai Lab Limited (ZLAB) fundamentals score
Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. It is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.3 out of 10, Weak long-term fundamentals
- Growth: 4.2/10
- Profitability: 2.2/10
- Financial health: 4.2/10
- Earnings quality: 7.3/10
- Valuation: 4.8/10
Scores are calculated from Zai Lab Limited’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10